Fosun Pharma (600196) Announces Acceptance of Subsidiary’s New Drug Registration Application

Bulletin Express

Feb 13

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, 600196) disclosed that its subsidiary, Jinzhou Avanc Pharmaceutical Co., Ltd., has recently received acceptance from the National Medical Products Administration for the drug registration application of Moxetomidate Hydrochloride Injection (ET-26). This Class 1 chemical medicine, recognized as a National Major Scientific and Technological Special Project for “Significant Drugs Development” in 2014, targets the induction and maintenance of anesthesia during short surgical procedures.

According to the announcement, Fosun Pharma’s cumulative research and development investment for this project stands at RMB 189.00 million (unaudited) as of January 2026. Market data indicates that drugs for similar uses recorded total sales of RMB 4,238.00 million in 2024. The acceptance of this application does not have a material impact on the group’s current financial results.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1137162235"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1137162235\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1137162235?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 18:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137162235","market":"hk","top_or_hot":-1,"title":"Fosun Pharma (600196) Announces Acceptance of Subsidiary’s New Drug Registration Application","media":"Bulletin Express","content":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, 600196) disclosed that its subsidiary, Jinzhou Avanc Pharmaceutical Co., Ltd., has recently received acceptance from the National Medical Products Administration for the drug registration application of Moxetomidate Hydrochloride Injection (ET-26). This Class 1 chemical medicine, recognized as a National Major Scientific and Technological Special Project for “Significant Drugs Development” in 2014, targets the induction and maintenance of anesthesia during short surgical procedures.</p>\n<p>According to the announcement, Fosun Pharma’s cumulative research and development investment for this project stands at RMB 189.00 million (unaudited) as of January 2026. Market data indicates that drugs for similar uses recorded total sales of RMB 4,238.00 million in 2024. The acceptance of this application does not have a material impact on the group’s current financial results.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma (600196) Announces Acceptance of Subsidiary’s New Drug Registration Application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma (600196) Announces Acceptance of Subsidiary’s New Drug Registration Application\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-13 18:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, 600196) disclosed that its subsidiary, Jinzhou Avanc Pharmaceutical Co., Ltd., has recently received acceptance from the National Medical Products Administration for the drug registration application of Moxetomidate Hydrochloride Injection (ET-26). This Class 1 chemical medicine, recognized as a National Major Scientific and Technological Special Project for “Significant Drugs Development” in 2014, targets the induction and maintenance of anesthesia during short surgical procedures.</p>\n<p>According to the announcement, Fosun Pharma’s cumulative research and development investment for this project stands at RMB 189.00 million (unaudited) as of January 2026. Market data indicates that drugs for similar uses recorded total sales of RMB 4,238.00 million in 2024. The acceptance of this application does not have a material impact on the group’s current financial results.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"复星医药","start_time":0,"source_url":"","article_id":"1137162235","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137162235","pubTimestamp":1770976947,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, 600196) disclosed that its subsidiary, Jinzhou Avanc Pharmaceutical Co., Ltd., has recently received acceptance from the National...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02196":"复星医药"},"translate_title":"复星医药(600196)公告子公司新药注册申请受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02196":1},"content_text":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, 600196) disclosed that its subsidiary, Jinzhou Avanc Pharmaceutical Co., Ltd., has recently received acceptance from the National Medical Products Administration for the drug registration application of Moxetomidate Hydrochloride Injection (ET-26). This Class 1 chemical medicine, recognized as a National Major Scientific and Technological Special Project for “Significant Drugs Development” in 2014, targets the induction and maintenance of anesthesia during short surgical procedures.\nAccording to the announcement, Fosun Pharma’s cumulative research and development investment for this project stands at RMB 189.00 million (unaudited) as of January 2026. Market data indicates that drugs for similar uses recorded total sales of RMB 4,238.00 million in 2024. The acceptance of this application does not have a material impact on the group’s current financial results.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}